Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cyclacel Pharmaceuticals ( (CYCC) ) is now available.
Cyclacel Pharmaceuticals reported its second quarter 2025 financial results, highlighting several key developments. The company declared quarterly cash dividends in April and June, entered a share exchange agreement with FITTERS Diversified Berhad in May, and completed a securities purchase agreement in June. Additionally, Cyclacel implemented a reverse stock split in July to meet Nasdaq’s share bid price requirements. Financially, the company saw a decrease in research and development expenses due to the liquidation of its UK subsidiary and a reduction in general and administrative expenses. The net loss for the quarter was reduced to $1.3 million compared to $3.3 million in the same period in 2024.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology. The company is working on a diversified pipeline of novel drug candidates targeting oncology and hematology indications.
Average Trading Volume: 1,882,317
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.7M
For detailed information about CYCC stock, go to TipRanks’ Stock Analysis page.